FORM 4

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	OVAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- KUMAR AMIT			2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner						
	KA BIOSC	(First) IENCES, INC., SSWAY, SUITI		3. Date of Earliest Transaction (Month/Day/Year) 12/23/2020					X Officer (give title below) Other (specify below) Chief Executive Officer							
SAN JOSE	E CA 051	(Street)		4. If An	nend	lment, Date (Origin	al Filed(Mo	onth/Day/	Year)		Individual or Jo Form filed by One Form filed by Mor	Reporting Per	son	icable Line)	
(City)	**	(State)	(Zip)			Т	able	I - Non-De	erivativ	e Securiti	es Acquire	d, Disposed of,	or Benefic	ially Owned		
1.Title of Sec (Instr. 3)	curity		2. Transaction Date (Month/Day/Yea	ar) any	utio	n Date, if C			(A) or 1	urities Acqu Disposed o 3, 4 and 5)	of (D) Ow Tra	Amount of Secu vned Following ansaction(s)		Č	wnership orm:	7. Nature of Indirect Beneficial
				(Moi	nth/Σ	Day/Year)	Cod	e V	Amoun	(A) or	Price (In	str. 3 and 4)		0 (1	r Indirect	Ownership (Instr. 4)
Reminder: Ro	eport on a sep	parate line for each o	Class of securities be	I - Deriv	ativ	re Securities	Acqı	Person this fo curren	orm are ntly val	not required id OMB c	ired to resonant				SEC 1	474 (9-02)
Security or Exerci (Instr. 3) Price of		Conversion Date Execution Date, in present the present of Derivative Conversion Date (Month/Day/Year) Execution Date, in present the prese			4. 5. Numb Transaction Derivativ Code Securitie			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an	d Amount of g Securities nd 4)		9. Number of Derivative Securities Beneficially Owned Following Reported	Form of Derivative Security: Direct (D) or Indirect) [`	
				Code	v	(A)	(D)	Date Exercisal		oiration e	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(I) (Instr. 4)	
Employee Stock Option (Right to Buy) (1)	\$ 2.83	12/23/2020		A		1,000,000		(2)	12/	/23/2030	Commo	n 1,000,000	\$ 0	1,000,000	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
KUMAR AMIT C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE,, CA 95118	X		Chief Executive Officer				

Signatures

/s/ Amit Kumar	12/28/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
- $\textbf{(2)} \ \ \text{The options vest and become exercisable in thirty-six (36) equal monthly installments beginning December 31, 2020.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.